miR-4516 predicts poor prognosis and functions as a novel oncogene via targeting PTPN14 in human glioblastoma

Glioblastomas (GBMs) are the most aggressive primary brain tumors, with an average survival of less than 15 months. Therefore, there is a critical need to develop novel therapeutic strategies for GBM. This study aimed to assess the prognostic value of miR-4516 and investigate its oncogenic functions...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncogene
Egile Nagusiak: Cui, Tiantian, Bell, Erica Hlavin, McElroy, Joseph, Becker, Aline Paixao, Gulati, Pooja Manchanda, Geurts, Marjolein, Mladkova, Nikol, Gray, Ashley, Liu, Kevin, Yang, Linlin, Liu, Ziyan, Fleming, Jessica, Haque, S. Jaharul, Barnholtz-Sloan, Jill S., Ligon, Keith L., Beroukhim, Rameen, Robe, Pierre, Chakravarti, Arnab
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6497411/
https://ncbi.nlm.nih.gov/pubmed/30559405
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41388-018-0601-9
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak